Kyntra Bio (KYNB) Cash from Operations (2014 - 2026)
Kyntra Bio (KYNB) posted Cash from Operations of 13887000.0 for Q1 2026, up 24.23% sequentially from 18328000.0 in Q4 2025, and down 610.74% YoY from 2719000.0 in Q1 2025.
Kyntra Bio (KYNB) Cash from Operations (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Cash from Operations for 13 years, with the latest figure at 13887000.0 in Q1 2026.
- Quarterly Cash from Operations fell 610.74% year-over-year to 13887000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21380000.0 (up 71.87% YoY) and the FY2025 annual result came in at 4774000.0, up 96.54% from the prior year.
- Cash from Operations rose to 13887000.0 in Q1 2026 per KYNB's latest filing, from 18328000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 12682000.0 in Q2 2025 and troughed at 110571000.0 in Q2 2023.
- A 5-year average of 36330235.29 and a median of 30466000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations slumped 1098.57% in 2023, then soared 131.81% in 2025.
- Over 5 years, Cash from Operations stood at 52513000.0 in 2022, then jumped by 65.11% to 18321000.0 in 2023, then sank by 66.29% to 30466000.0 in 2024, then soared by 39.84% to 18328000.0 in 2025, then climbed by 24.23% to 13887000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 13887000.0, 18328000.0, and 1847000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | -3.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.99 Mn |
| Jun 30, 2026 | -3.99 Mn |
| Mar 31, 2026 | -13.89 Mn |
| Mar 31, 2026 | -13.89 Mn |
| Dec 31, 2025 | -18.33 Mn |
| Dec 31, 2025 | -18.33 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | 12.68 Mn |
| Jun 30, 2025 | 12.68 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | -30.47 Mn |
| Dec 31, 2024 | -30.47 Mn |
| Sep 30, 2024 | -8.38 Mn |
| Sep 30, 2024 | -8.38 Mn |
| Jun 30, 2024 | -39.87 Mn |
| Jun 30, 2024 | -39.87 Mn |
| Mar 31, 2024 | -59.29 Mn |
| Mar 31, 2024 | -59.29 Mn |